Multiple Myeloma Coverage from Every Angle

Sagar Lonial, MD, on Clinical Implications of New Data on CAR T-Cell Treatments for Multiple Myeloma

Posted: Tuesday, December 8, 2020

Sagar Lonial, MD, of the Emory University School of Medicine, discusses what he sees as encouraging findings on second-generation CAR T-cell treatments, toxicity concerns, and the question of whether these therapies can be offered outside of centers that specialize in treating patients with multiple myeloma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.